Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × lirilumab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Carcinoma, Squamous Cell 1

Interventions

Surveys and Questionnaires 98 Exercise 88 Blood Specimen Collection 86 Radiotherapy 60 Gemcitabine 53 Bevacizumab 52 Cisplatin 50 Standard of Care 49 Capecitabine 47 Dexamethasone 44 Cyclophosphamide 44 Carboplatin 44 Docetaxel 41 Paclitaxel 40 Interviews as Topic 40 pembrolizumab 39 Oxaliplatin 38 Methods 35 Irinotecan 35 Fluorouracil 35 Magnetic Resonance Spectroscopy 33 Therapeutics 29 Radiosurgery 28 Nivolumab 27 Drug Therapy 26 Educational Status 25 Leucovorin 22 Everolimus 21 Control Groups 21 Cognitive Behavioral Therapy 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡